The short version of lactam bridge fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-02. Anything still debated is marked as such rather than presented as settled.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
A system of differential equations for concentration or quantity of substance on each compartment can be written, and its parameters represent blood flows, pulmonary ventilation rate, organ volumes etc., for which information is available in scientific publications. Indeed, the description they make of the body is simplified and a balance needs to be struck between complexity and simplicity. Besides the advantage of allowing the recruitment of a priori information about parameter values, these models also facilitate inter-species transpositions or extrapolation from one mode of administration to another (e.g., inhalation to oral). An example of a 7-compartment PBPK model, suitable to describe the fate of many solvents in the mammalian body, is given in the Figure on the right.
SPECULOOS-3 b, an exoplanet nearly identical in size to Earth, is discovered orbiting an ultracool dwarf star as small as Jupiter and located 55 light-years from Earth. Solar energy is combined with synthetic quartz to generate temperatures of more than 1,000°C. This proof-of-concept method shows the potential of clean energy to replace fossil fuels in heavy manufacturing, according to a research team at ETH Zurich. 16 May – A multimodal algorithm for improved sarcasm detection is revealed. Trained on a database known as MUStARD, it can examine multiple aspects of audio recordings and has 75% accuracy. 17 May – The world's smallest quantum light detector on a silicon chip is demonstrated, 50 times smaller than their previous version. 20 May – The first measurements of an exoplanet's core mass are obtained by the James Webb Space Telescope. This reveals a surprisingly low amount of methane and a super-sized core within the super-Neptune WASP-107b. 23 May New images from the Euclid space telescope are published, including a view of the Messier 78 star nursery. Astronomers using TESS report the discovery of Gliese 12 b, a Venus-sized exoplanet located 40 light-years away, with an equilibrium temperature of 315 K (42 °C; 107 °F). This makes it the nearest, transiting, temperate, Earth-sized world located to date. A team shows that iron instead of cobalt and nickel can be used as a cathode material in lithium-ion batteries, improving both safety and sustainability.
== Synthetic insecticides == Insecticides are most usefully categorised according to their modes of action. The insecticide resistance action committee (IRAC) lists 30 modes of action plus unknowns. There can be several chemical classes of insecticide with the same mode or action. IRAC lists 56 chemical classes plus unknowns. The mode of action describes how the insecticide kills or inactivates a pest.
== Notable people == Jacob M. Gile (1849–1937), architect in Colorado, born in Lebanon Doug Jones, MLB All-Star relief pitcher Mel Kenyon, Hall of Fame midget car driver; had four top-five finishes in Indianapolis 500 Sylvia Likens, murder victim, born in Lebanon, murdered in Indianapolis in 1965 when she was 16 Ray Long, editor of Cosmopolitan from 1919 to 1931, born in Lebanon Ami McKay, novelist, playwright and journalist Rick Mount, 1966 Indiana "Mr. Basketball" award recipient, 3x All-American Purdue player William Perigo, basketball head coach at Western Michigan University and University of Michigan Drew Powell, actor, is best known for his role as Hoss Cartwright on the TV series Ponderosa Allen Saunders, cartoonist and writer, Mary Worth G. Thomas Tanselle, textual critic, bibliographer, and book collector, especially known for his work on Herman Melville Craig Terrill, former Purdue and Seattle Seahawks football player Herman B Wells, former President of Indiana University, attended Lebanon High School
Sources: en.wikipedia.org
== Analogue controls == Several jurisdictions have implemented analogue law controls of fentanyl analogues in an attempt to pre-emptively ban novel derivatives before they appear on the market. One representative example is the New Zealand provisions enacted in 1988 in response to the first wave of fentanyl derivatives. This bans a set of structures as follows; "Fentanyl analogues, in which the N-[1-(2-phenethyl)-4-piperidyl]aniline nucleus has additional radicals, either alone or in combination, attached as follows: (a) an acetyl, propionyl, butenoyl or butanoyl radical, attached to the aniline nitrogen atom: (b) 1 or more alkyl radicals, with up to 10 carbon atoms in total, attached to the ethyl moiety: (c) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to each of the benzene rings." A more recent and somewhat broader example was introduced into US Federal legislation in 2018, covering the following structures; "...fentanyl-related substances includes any substance not otherwise controlled in any schedule...that is structurally related to fentanyl by one or more of the following modifications:
Low levels of glycogen branching enzyme leads to a condition known as glycogen-branching enzyme deficiency. This condition is caused by a mutation of the GBE1 gene responsible for producing the glycogen branching enzyme. Subsequently, glycogen molecules are produced with few branches, which greatly decreases the number of nonreducing ends, drastically slowing the rate at which the molecule can be synthesized or broken down. This causes low levels of muscle glycogen that is very resistant to amylase. This disease is usually seen in Quarter Horse foals and is fatal.
3) Regulations 1993 (S.I. 1993/1540) Firearms (Dangerous Air Weapons) (Scotland) Amendment Rules 1993 (S.I. 1993/1541) First Community National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1543) Mental Health Foundation of Mid Staffordshire National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1544) Special Trustees for the Royal London Hospital (Transfer of Trust Property) Order 1993 (S.I. 1993/1545) Child Resistant Packaging (Safety) (Amendment) Regulations 1993 (S.I. 1993/1546) Toys (Safety)(Amendment) Regulations 1993 (S.I. 1993/1547) Addenbrooke's National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1564) Foreign Fields (Specification) (Amendment) Order 1993 (S.I. 1993/1565) Foreign Fields (Specification) (No. 2) Order 1993 (S.I. 1993/1566) Reconstitution of the Dearne and Dove Internal Drainage Board Order 1993 (S.I. 1993/1570) European Communities (Designation)(No. 2) Order 1993 (S.I. 1993/1571) House of Commons Disqualification Order 1993 (S.I. 1993/1572) Child Abduction and Custody (Parties to Conventions) (Amendment) (No. 2) Order 1993 (S.I. 1993/1573) Extradition (Hijacking) (Amendment) Order 1993 (S.I. 1993/1574) Iraq (United Nations) (Sequestration of Assets) (Isle of Man) Order 1993 (S.I. 1993/1575) Family Law (Northern Ireland) Order 1993 (S.I. 1993/1576) Family Law (Northern Ireland Consequential Amendments) Order 1993 (S.I. 1993/1577) Fire Services (Amendment) (Northern Ireland) Order 1993 (S.I. 1993/1578) Social Security (Amendment) (Northern Ireland) Order 1993 (S.I.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.